Erratum : Isoindolone derivative QSN-10c induces leukemic cell apoptosis and suppresses angiogenesis via PI3K/AKT signaling pathway inhibition (Acta Pharmacologica Sinica 35 (625-35) 10.1038/aps.2013.194);Isoindolone derivative QSN-10c induces leukemic cell apoptosis and suppresses angiogenesis via PI3K/AKT signaling pathway inhibition

Acta Pharmacologica Sinica

Volumn 35, Issue 5, 2014, Pages 625-635

  Lv, Wen Wen ^a,b   Qin, Si Ning ^b   Chen, Cong Qin ^b   Zhang, Jin Jie ^b   Ren, Tian Shu ^a   Xu, Yong Nan ^b   Zhao, Qing Chun ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

AKT; angiogenesis; anticancer drug; apoptosis; GSK3 ; isoindolone; leukemia; zebrafish

Indexed keywords

2 (4,6 DIMETHOXY 1,3 DIOXOISOINDOLIN 2 YL)ETHYL 2 CHLOROACETATE; CYTOCHROME C; GLYCOGEN SYNTHASE KINASE 3BETA; ISOINDOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ISOINDOL-1-ONE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; EMBRYO; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; CELL LINE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYTOCHROMES C; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOINDOLES; K562 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZEBRAFISH;

EID: 84927170318     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.49     Document Type: Erratum

References (47)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
3. Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-44.
4. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162-9.
5. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008; 143: 622-31.
6. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
7. El Sayed KA. Natural products as angiogenesis modulators. Mini Rev Med Chem 2005; 5: 971-93.
8. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-70.
9. Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008; 153: 936-46.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
11. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-51.
12. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
13. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000; 19: 59-65.
14. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
15. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000; 275: 5096-103.
16. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999; 274: 16349-54.
17. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-50.
18. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997; 15: 2169-77.
19. Lv WW, Gao YJ, Su MZ, Luo Z, Zhang W, Shi GB, et al. Isoindolones from Lasiosphaera fenzlii Reich and their bioactivities. Helv Chim Acta 2013; 96: 109-13.
20. Qin SN, Lv WW, Wang Q, Zhao QC, Xu YN. Design, synthesis and biological evaluation of N-substituted phthalimide derivative. Chem J Chinese U 2013; 34: 2745-51.
21. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
22. Tang JY, Li S, Li ZH, Zhang ZJ, Hu G, Cheang D, et al. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 2010; 5: e11822.
23. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277: 41046-59.
24. Zhao J, Zhao L, Chen W, He LC, Li X. Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways. Biomed Pharmacother 2008; 62: 383-9.
25. Liu KK, He QX, Yuan YQ, Han LW, Peng WB, et al. Inventors; Biology Institute of Shandong Academy of Sciences, assignee. Methods of screening for anti-angiogenic active substances: CN102445531A. 2012 May 9.
26. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003; 17: 1547-9.
27. Jendrossek V, Muller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 2003; 22: 2621-31.
28. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000; 19: 4563-73.
29. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001; 97: 1378-87.
30. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003; 17: 2481-95.
31. Tavani A, La Vecchia C. Fruit and vegetable consumption and cancer risk in a Mediterranean population. Am J Clin Nutr 1995; 61: 1374S-1377S.
32. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004; 117: 3-32.
33. Shibuya M. Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006; 13: 63-9.
34. Matsunaga N, Shimazawa M, Otsubo K, Hara H. Phosphatidylinositol inhibits vascular endothelial growth factor-A-induced migration of human umbilical vein endothelial cells. J Pharmacol Sci 2008 106: 128-35.
35. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A. Thalidomide: a new anticancer drug. Expert Opin Investig Drugs 2003; 12: 1211-25.
36. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827-34.
37. Marks MG, Shi J, Fry MO, Xiao Z, Trzyna M, Pokala V, et al. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the Chorioallantoic Membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull 2002; 25: 597-604.
38. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 2003; 63: 3189-94.
39. Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z, et al. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 2006; 78: 2558-63.
40. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase akt. Circ Res 2000; 86: 892-6.
41. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normo-cholesterolemic animals. Nat Med 2000; 6: 1004-10.
42. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000; 477: 258-62.
43. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-98.
44. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-30.
45. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996; 87: 619-28.
46. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
47. Kim KH, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Kim HS, et al. Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation. Pharm Res 2011; 28: 597-609.